Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Erwin Dreesen
Observed names:
Dreesen, E.,
Dreesen, Erwin,
E Dreesen,
E. Dreesen
Institution:
KU Leuven
Observed institutions:
Uppsala University,
Vrije Universiteit Brussel,
University of California, San Francisco,
University of California System,
Kliničko Bolnički Centar Zvezdara,
Syngene International (India),
Takeda (Japan),
University of Glasgow,
UCLouvain,
KU Leuven
show all 10
ORCID:
0000-0002-0785-2930
Observed ORCID:
0000-0002-0785-2930
OpenAlex ID:
A5024846292
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity
2021
·
L. Vanderbeke
, P. Van Mol
, et al.
·
Nature Communications
·
244
PDF
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
2018
·
Erwin Dreesen
, Bram Verstockt
, et al.
·
Clinical Gastroenterology and Hepatology
·
158
Model-informed precision dosing: State of the art and future perspectives
2024
·
I.K. Minichmayr
, E. Dreesen
, et al.
·
Advanced Drug Delivery Reviews
·
153
PDF
Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
2020
·
Wannee Kantasiripitak
, Ruth Van Daele
, et al.
·
Frontiers in Pharmacology
·
131
PDF
Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
2019
·
Bram Verstockt
, Erwin Dreesen
, et al.
·
Journal of Crohn s and Colitis
·
120
PDF
Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
2022
·
E. Sally Ward
, Deborah Gelinas
, et al.
·
Frontiers in Immunology
·
119
PDF
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
2019
·
Erwin Dreesen
, Filip Baert
, et al.
·
Clinical Gastroenterology and Hepatology
·
89
PDF
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
2019
·
Severine Vermeire
, Erwin Dreesen
, et al.
·
Clinical Gastroenterology and Hepatology
·
87
PDF
Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis
2016
·
Iris Detrez
, Erwin Dreesen
, et al.
·
Journal of Crohn s and Colitis
·
76
PDF
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease
2016
·
Thomas Billiet
, Erwin Dreesen
, et al.
·
The American Journal of Gastroenterology
·
70
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
2018
·
Karen van Hoeve
, Erwin Dreesen
, et al.
·
Journal of Crohn s and Colitis
·
65
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
2017
·
Erwin Dreesen
, Peter Bossuyt
, et al.
·
Clinical Pharmacology Advances and Applications
·
63
PDF
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission
2020
·
Jurij Hanžel
, Jurij Zdovc
, et al.
·
Clinical Gastroenterology and Hepatology
·
51
Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response
2017
·
E. Dreesen
, T. Van Stappen
, et al.
·
Alimentary Pharmacology & Therapeutics
·
46
PDF
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples
2016
·
Ann Gils
, Thomas Van Stappen
, et al.
·
Inflammatory Bowel Diseases
·
46
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease
2019
·
Karen van Hoeve
, Erwin Dreesen
, et al.
·
Journal of Pediatric Gastroenterology and Nutrition
·
43
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study
2019
·
Niels Vande Casteele
, Filip Baert
, et al.
·
Journal of Crohn s and Colitis
·
42
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients
2019
·
Bram Verstockt
, Evelien Mertens
, et al.
·
Journal of Crohn s and Colitis
·
38
PDF
Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time
2017
·
Sumin Bian
, Erwin Dreesen
, et al.
·
Inflammatory Bowel Diseases
·
36
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
2022
·
Wannee Kantasiripitak
, An Outtier
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
35
PDF
Optimising infliximab induction dosing for patients with ulcerative colitis
2019
·
Erwin Dreesen
, Ruben Faelens
, et al.
·
British Journal of Clinical Pharmacology
·
35
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease
2019
·
Karen van Hoeve
, Erwin Dreesen
, et al.
·
Therapeutic Drug Monitoring
·
33
PDF
Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
2021
·
Zhigang Wang
, Bram Verstockt
, et al.
·
British Journal of Clinical Pharmacology
·
32
Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial
2021
·
Laurens Liesenborghs
, Isabel Spriet
, et al.
·
EBioMedicine
·
32
PDF
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases
2023
·
Wannee Kantasiripitak
, Sebastian G Wicha
, et al.
·
Journal of Crohn s and Colitis
·
31
PDF
Show more works
View as search
Works count:
212
Citation count:
2,777
H-index:
28
I10-index:
60
Year
Topic
Type
